RATIONALE: Several studies have examined the role of different neurotransmitter systems in modulating risk-taking behavior. OBJECTIVE: This investigation was aimed to determine whether the benzodiazepine lorazepam dose-dependently alters risk-taking behavior and underlying neural substrates. MATERIALS AND METHODS:Fifteen healthy, nonsmoking, individuals (six women, nine men), aged 18-39 years (mean 27.6 +/- 1.4 years) with 12-18 years of education (mean 15.6 +/- 0.3 years) underwent functional magnetic resonance imaging while performing a risk-taking decision-making task. RESULTS: Our results show that lorazepam did not affect risky behavior at 0.25 and 1 mg, but dose-dependently attenuated activation in (a) the amygdala and medial prefrontal cortex during the response selection phase, and in (b) the bilateral insular cortex and amygdala during the outcome (i.e., rewarded or punished) phase. Furthermore, a lorazepam-induced increase in insular cortex activation was associated with less risky responses. CONCLUSIONS: Taken together, our findings support the idea that GABAergic modulation in limbic and paralimbic structures is important during both the response selection and outcome phase of risk-taking decision-making.
RCT Entities:
RATIONALE: Several studies have examined the role of different neurotransmitter systems in modulating risk-taking behavior. OBJECTIVE: This investigation was aimed to determine whether the benzodiazepine lorazepam dose-dependently alters risk-taking behavior and underlying neural substrates. MATERIALS AND METHODS: Fifteen healthy, nonsmoking, individuals (six women, nine men), aged 18-39 years (mean 27.6 +/- 1.4 years) with 12-18 years of education (mean 15.6 +/- 0.3 years) underwent functional magnetic resonance imaging while performing a risk-taking decision-making task. RESULTS: Our results show that lorazepam did not affect risky behavior at 0.25 and 1 mg, but dose-dependently attenuated activation in (a) the amygdala and medial prefrontal cortex during the response selection phase, and in (b) the bilateral insular cortex and amygdala during the outcome (i.e., rewarded or punished) phase. Furthermore, a lorazepam-induced increase in insular cortex activation was associated with less risky responses. CONCLUSIONS: Taken together, our findings support the idea that GABAergic modulation in limbic and paralimbic structures is important during both the response selection and outcome phase of risk-taking decision-making.
Authors: Scott D Lane; Don R Cherek; Oleg V Tcheremissine; Lori M Lieving; Cythia J Pietras Journal: Neuropsychopharmacology Date: 2005-04 Impact factor: 7.853
Authors: Tony T Yang; Alan N Simmons; Scott C Matthews; Susan F Tapert; Amanda Bischoff-Grethe; Guido K W Frank; Estibaliz Arce; Martin P Paulus Journal: Neurosci Lett Date: 2007-11-27 Impact factor: 3.046
Authors: Robin L Aupperle; Lakshmi Ravindran; Dharol Tankersley; Taru Flagan; Nathan R Stein; Alan N Simmons; Murray B Stein; Martin P Paulus Journal: Neuropsychopharmacology Date: 2011-03-23 Impact factor: 7.853
Authors: Peter van Ruitenbeek; Annemiek Vermeeren; Mitul Ashok Mehta; Eva Isabell Drexler; Willem Jan Riedel Journal: Hum Brain Mapp Date: 2013-10-18 Impact factor: 5.038
Authors: Alan N Simmons; Estibaliz Arce; Kathryn L Lovero; Murray B Stein; Martin P Paulus Journal: Int J Neuropsychopharmacol Date: 2009-06-23 Impact factor: 5.176
Authors: Estibaliz Arce; Alan N Simmons; Kathryn L Lovero; Murray B Stein; Martin P Paulus Journal: Psychopharmacology (Berl) Date: 2007-12-06 Impact factor: 4.530
Authors: Darren Schreiber; Greg Fonzo; Alan N Simmons; Christopher T Dawes; Taru Flagan; James H Fowler; Martin P Paulus Journal: PLoS One Date: 2013-02-13 Impact factor: 3.240